Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2 million is not enough volume?
Okaaayyy....
dr_Pierce sounds a lot more convincing then Punit, must admit
oh okay :)
Well I am a Jbem fan too, but still have all my shares of AVXL and TPIV 'cause I fundamentally believe in their science. I did sell out to TNXP lately. (less convinced)
disregard
and more to come soon!
Today will be day 5 above $1, only 5 more and Dart has to pay up
thats exactly why I never chase. It seems the dust is already settling a bit now.
And I presume you are looking to make that buck in the shorter rather then longer timeframe?
That is what our "nice guy" dr_Pierce said on June 17th
oh there are many good trolls around Blu!
I have personal experience over at the ONCS forum. They made the troll even a moderator so he could be more effective in scaring retails.
It has to cool down a bit after yesterday, so lets say hovering between 1.4 and 1.5?
yeah its running up like crazy.
Will not chase it with the herd but wait for a cool down
Hi wait
You make great reading and it makes sense. Start off with an observation, analyze the situation, make your argument and then if need be, mitigate.
In case there is anybody around here that is interested in what Oncosec is all about, go listen to this webcast from June 17th. Dr_Pierce, chief science officer, explains the different hypotheses and trials.
Full MCC data will be released soon. He also refers to the combo-trial with Keytruda as "starting soon".
Go listen and make your own opinions.
http://www.veracast.com/webcasts/bio/internationalconvention2015/36207412931.cfm
150k per treatment? Good luck finding governments or health insurance to agree to this.
Sovaldi at 90k by Gilead was already a big issue.
It's a very binary question: either you want ONCS to succeed or eithere you don't
Ugh another junk piece by Readers Digest
Focus on content rather then spelling. I am not native English
You missed the Nature article co-authored by dr Pierce
So Fda approval is your only criterium to say wether a drug works?
So results of a p1, p2 or p3 are meaningless?
FDA approval does not fall out of the blue
You go through all the hoops first. ONCS has passee 2nd hoop in mono-melanoma and is trying it in other indications (fact aswell)
Oh those were mostly facts I was giving.
But hey we are making progress acknowledging that opinions are subjective
The clinical studies are anything but meaningless as they are designed to validate a concept.
You do not do that with hundreds of patients. Once the hypothesis is proven, then you take it fom there
We know the mono works in melanoma. It will be tested in triple negative breast and head and neck.
Furthermore ONCS will test wether a combination with Keytruda yields better ORR or not. Coupke this with biomarkers to pretest a patient (Plexikon and Heat)
Last but not least, R&D ito a new electroporation device that can go anyway.
So yes ONCS has a lot of balls in the air
Well then we have a tit for tat.
Opinions are subjective.
My dilligence tells me we are on an upway path, strengthend with fresh cash and an increased institutional base.
Thanks for your kind and helpfull words.
Then I think you forgot to press the submit button
1) CEO's salary says it all you claim. Please expand
2) Ridgeback has a history of dumping shares quicky. Show us the history
See when you make these statements, you have to give the facts aswell. And I presume you have done your DD before making these, so why not show it to the rest of us?
Well he learns from the best!
A shareprice can move 3 ways: up, down or sidewise.
So you have a 33% chance that you are right
The rest is speculation
Funny definition of helping.
Show us your fact for making ONCS statements
Thank you for sharing your opinion
Now what about the facts on your previous statements regarding the CEO and Ridgeback ?
Would you reckon they will hold off releasing new data until the warrants at 1$ are exercised?
So another 7 trading days at least.
Just a friendly reminder that there are still outstanding questions regarding your statements.
Facts about Oncosec:
- clear hypotheses formulated by dr_Pierce
- initiation of several trials in different indications
- reverse split executed
- reduced float
- reduced possibility for market manipulation due uplisting to NASDAQ
- 13,6 mil direct offering executed, increases institutional shareholder base
- continued expansion of the company and hiring of key people
- expanded R&D into a new electroporation device that can go anywhere in the body
Key dates:
March 23: webinar hosted
May 14th: reverse split announced
May 18th: reverse split executed
May 29th: uplisting to NASDAQ
June 3d: direct offering announced
June 9th: new institutional shareholder, Sabby management
June 16th: First patient enrollment in Squamous Cell Carcinoma of the Head and Neck Phase II Clinical Trial
June 18th: new institutional shareholder, Ridgeback capital
June 26th: ONCS to be included in Russell Microcap index
Still to be announced: first patient enrollment in combination trial P2B with Keytruda
I stand corrected. Thank you TOB
George, I like your enthusiasm and hope your prediction becomes reality.
But I have to ask what your sources are to make this statement?
Whishfull thinking or do you know something that we are not privy of?
What are the listing requirements for the Nasdaq?
There is a set of rules all companies have to meet:
- minimum 1,250,000 publicly traded shares
- regular bid price of $4 at the time of listing (can be less but then other requirements)
- 3 market makers
- have at least 450 round lot (100 shares) shareholders, 2,200 total shareholders, or 550 total shareholders with 1.1 million average trading volume over the past 12 months
In addition to these requirements, companies must meet all of the criteria under at least one of the following standards.
Listing Standard No. 1
The company must have aggregate pre-tax earnings in the prior three years of at least $11 million, in the prior two years at least $2.2 million, and no one year in the prior three years can have a net loss.
Listing Standard No. 2
The company must have a minimum aggregate cash flow of at least $27.5 million for the past three fiscal years, with no negative cash flow in any of those three years. In addition, its average market capitalization over the prior 12 months must be at least $550 million, and revenues in the previous fiscal year must be $110 million, minimum.
Listing Standard No. 3
Companies can be removed from the cash flow requirement of Standard No. 2 if the average market capitalization over the past 12 months is at least $850 million, and revenues over the prior fiscal year are at least $90 million.
Fan, on what do you base your prediction?
I would call them market manipulators!
Please explain what Punit Dhillon's salary as CEO of ONCS means in the bigger picture,as you imply it means a whole lot more.
dr_lowenstein Member Level Saturday, 06/20/15 01:22:12 PM
Re: TomP1 post# 30837
Post # of 30840
actually it tells us a whole lot more
Please explain and show your DD that backups your claim that Ridgeback has a history as a hedgefund to go into a stock and then quickly dump their shares afterwards and therefore you anticipate the same will happen to ONCS
dr_lowenstein Member Level Friday, 06/19/15 12:33:43 PM
Re: TomP1 post# 30807
Post # of 30840
Savvy investors recognize that Ridgeback is a HEDGE fund. IE a trader, nothing to get too excited about until one examines how long they hold the stock
well then educate us what it says.
Ridgeback: if you are claiming that they will dump their ONCS shares sooner rather then later, based on their historical pattern, then show us your DD.
Well actually it tells you nothing except that this is his wage.
Doc, you are trying to turn tables on me.
As you are trying to allude that Ridge could sell their shares quickly, I well let you make the case and show us the candy.
You seem to say that you have already done your DD on how long Ridge holds shares in new investment. Surely it cannot be asked to much to share that DD with us.